End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
124 MXN | -2.36% | -.--% | -2.36% |
Sales 2024 * | 3.94Cr 66Cr 327.46Cr | Sales 2025 * | 5.82Cr 97Cr 484Cr | Capitalization | 7.09Cr 118.08Cr 589.64Cr |
---|---|---|---|---|---|
Net income 2024 * | -12Cr -199.96Cr -998.48Cr | Net income 2025 * | -7.7Cr -128.31Cr -640.69Cr | EV / Sales 2024 * | -1.44 x |
Net cash position 2024 * | 13Cr 212.37Cr 1.06TCr | Net cash position 2025 * | 5.45Cr 91Cr 453.74Cr | EV / Sales 2025 * | 0.28 x |
P/E ratio 2024 * |
-0.65
x | P/E ratio 2025 * |
-1.24
x | Employees | 166 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.02% |
Latest transcript on Marinus Pharmaceuticals, Inc.
1 day | -2.36% | ||
3 months | -2.36% | ||
6 months | -4.62% | ||
Current year | -2.36% |
Managers | Title | Age | Since |
---|---|---|---|
Scott Braunstein
CEO | Chief Executive Officer | 60 | 05/18/05 |
Steven Pfanstiel
DFI | Director of Finance/CFO | 51 | 12/21/12 |
Joseph Hulihan
CTO | Chief Tech/Sci/R&D Officer | 68 | 06/19/06 |
Members of the board | Title | Age | Since |
---|---|---|---|
Tim Mayleben
BRD | Director/Board Member | 63 | 01/08/01 |
Scott Braunstein
CEO | Chief Executive Officer | 60 | 05/18/05 |
Elan Ezickson
BRD | Director/Board Member | 60 | 12/19/12 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+37.74% | 72TCr | |
+34.54% | 59TCr | |
-2.07% | 37TCr | |
+20.25% | 33TCr | |
+2.99% | 28TCr | |
+16.81% | 24TCr | |
+10.04% | 21TCr | |
-4.54% | 21TCr | |
+7.43% | 17TCr |
- Stock Market
- Equities
- MRNS Stock
- MRNS * Stock